Evidence Hub

Platelet-derived biomaterials in osteoporosis: mechanisms, evidence and translational prospects

Hiruthyaswamy SP, Rao DR, Velavan P, Veeran T, Sakthivel YK, Deepankumar K

Journal of biological engineering, 2026

Abstract

Osteoporosis is a systemic skeletal disorder characterized by impaired bone microarchitecture and reduced bone strength arising from dysregulated coupling between osteoclast-mediated resorption and osteoblast-driven formation. Estrogen deficiency, chronic inflammation, oxidative stress, and altered RANKL/OPG signaling amplify osteoclastogenesis while suppressing Wnt/β-catenin-dependent osteoblast differentiation, resulting in progressive trabecular thinning and cortical porosity. Although antiresorptive agents and anabolic therapies reduce fracture risk, they do not fully restore bone quality, microvascular integrity, or osteoimmune balance. Platelet-derived biomaterials (PDBs), including platelet-rich plasma, platelet-rich fibrin, platelet lysates, and platelet-based hydrogels, represent autologous bioactive systems enriched with platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, insulin-like growth factor-1, and bioactive lipid mediators. Upon activation, PDBs provide an early burst and sustained release of growth factors within a fibrin matrix that supports mesenchymal stem cell recruitment, RUNX2- and Osterix-mediated osteogenic differentiation, extracellular matrix deposition, and angiogenic coupling through VEGF-driven neovascularization. Concurrently, PDBs modulate osteoclast activity by influencing the RANKL/OPG axis, promoting macrophage polarization toward an M2 reparative phenotype, and attenuating inflammatory…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free